Synonym
Butoctamide semisuccinate; M-2H; M 2H; M2H; Butoctamide hydrogen succinate;
IUPAC/Chemical Name
4-((4-((2-ethylhexyl)amino)-4-oxobutan-2-yl)oxy)-4-oxobutanoic acid
InChi Key
CQONVBIGUJWUFE-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H29NO5/c1-4-6-7-13(5-2)11-17-14(18)10-12(3)22-16(21)9-8-15(19)20/h12-13H,4-11H2,1-3H3,(H,17,18)(H,19,20)
SMILES Code
O=C(OC(C)CC(NCC(CC)CCCC)=O)CCC(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
315.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sasaki K, Furusawa S, Takayanagi G. [Butoctamide enhancement of the antitumor activity of 6-mercaptopurine on Ehrlich solid tumors in mice (author's transl)]. Nihon Yakurigaku Zasshi. 1981 Feb;77(2):131-9. Japanese. PubMed PMID: 6894582.
2: Mizuki Y, Suetsugi M, Hotta H, Ushijima I, Yamada M. Stimulatory effect of butoctamide hydrogen succinate on REM sleep in normal humans. Prog Neuropsychopharmacol Biol Psychiatry. 1995 May;19(3):385-401. PubMed PMID: 7624490.
3: Grubar JC, Gigli GL, Colognola RM, Ferri R, Musumeci SA, Bergonzi P. Sleep patterns of Down's syndrome children: effects of butoctamide hydrogen succinate (BAHS) administration. Psychopharmacology (Berl). 1986;90(1):119-22. PubMed PMID: 2945221.
4: Gigli GL, Grubar JC, Colognola RM, Amata MT, Pollicina C, Ferri R, Musumeci SA, Bergonzi P. Butoctamide hydrogen succinate and intensive learning sessions: effects on night sleep of Down's syndrome patients. Sleep. 1987 Dec;10(6):563-9. PubMed PMID: 2963363.
5: Hayashi Y, Otomo E, Okudaira N, Endo S. Drug-increased REM sleep in aged subjects: butoctamide hydrogen succinate (BAHS). Psychopharmacology (Berl). 1982;77(4):367-70. PubMed PMID: 6813899.
6: Okudaira N, Torii S, Endo S. The effect of butoctamide hydrogen succinate on nocturnal sleep: all-night polygraphical studies. Psychopharmacology (Berl). 1980;70(2):117-21. PubMed PMID: 6776569.
7: Tazaki T, Tada K, Nogami Y, Takemura N, Ishikawa K. Effects of butoctamide hydrogen succinate and nitrazepam on psychomotor function and EEG in healthy volunteers. Psychopharmacology (Berl). 1989;97(3):370-5. PubMed PMID: 2497487.
8: Gigli GL, Grubar JC, Bergonzi P, Maschio MC. Long-term administration of butoctamide hydrogen succinate on nocturnal sleep of mentally retarded subjects: a polygraphic study versus placebo. Psychopharmacology (Berl). 1995 Feb;117(4):438-42. PubMed PMID: 7604145.
9: Hayashi Y, Watanabe H, Okudaira N, Otomo E, Endo S. [The effects of butoctamide hydrogen succinate (BAHS) on the sleep of the aged people (author's transl)]. No To Shinkei. 1981 Dec;33(12):1243-50. Japanese. PubMed PMID: 7326156.
10: Kato S, Wakasa Y, Yanagita T. [Dependence study on butoctamide hydrogen succinate (M-2H) in rhesus monkeys]. Arukoru Kenkyuto Yakubutsu Ison. 1987 Dec;22(4):340-51. Japanese. PubMed PMID: 3449033.
11: Ohta T, Iwata T, Kayukawa Y, Okada T. Daily activity and persistent sleep-wake schedule disorders. Prog Neuropsychopharmacol Biol Psychiatry. 1992 Jul;16(4):529-37. PubMed PMID: 1641496.
